JMP Securities analyst Roy Buchanan believes immunogenicity and reactogenicity results for mod mRNA continue to support competitiveness of CureVac’s (CVAC) constructs. On Monday, the company announced updated results in older adults for the modified mRNA Phase 1s in both COVID-19 and flu. The results continue to look comparable and competitive with those presented by competitors and, in the firm’s view, support its belief that the technology is similarly competitive. CureVac and partner GSK (GSK) remain on track to start Phase 2 trials in both indications later this year, as well as the Phase 1s in oncology, JMP says. The firm reiterates an Outperform rating and risk-adjusted, DCF and comparable-company derived $34 price target on CureVac.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CVAC:
